Multiple Myeloma | Specialty

Emerging Combinations for Relapsed/Refractory Multiple Myeloma

June 13th 2015

Monitoring Response and Defining Complete Remission in Multiple Myeloma

June 13th 2015

Dr. Saad Usmani on Daratumumab Monotherapy for Multiple Myeloma

June 11th 2015

Saad Z. Usmani, MD, director, Clinical Research Hematologic Malignancies, director, Plasma Cell Disorders, Levine Cancer Institute/Carolinas Healthcare System, discusses daratumumab for patients with relapsed/refractory multiple myeloma.

Elotuzumab and Daratumumab Shown to Improve Outcomes in Multiple Myeloma

June 9th 2015

Sagar Lonial, MD, discusses the future of monoclonal antibodies in multiple myeloma.

2015 ASCO Annual Meeting Highlights

June 5th 2015

CD19-Targeted CAR T-Cell Therapy Shows Promise in Multiple Myeloma

June 5th 2015

The CD19-targeted chimeric antigen receptor T-cell therapy CTL019 demonstrated early evidence of activity and safety in patients with refractory multiple myeloma.

Dr. Philip McCarthy on Lenalidomide Maintenance for Multiple Myeloma

June 5th 2015

Philip McCarthy, MD, Professor of Oncology, Director, Blood and Marrow Transplant Center, Department of Medicine Roswell Park Cancer Institute, discusses the impact of the CALGB 100104 study which looked at lenalidomide maintenance following single autologous stem cell transplant for multiple myeloma.

Daratumumab Data Impresses in Myeloma, FDA Submission Expected

May 30th 2015

Daratumumab demonstrated a 65% one-year overall survival rate and a 29.2% objective response rate in patients with double refractory heavily pretreated multiple myeloma.

New Paradigm Emerging in Multiple Myeloma Therapy

May 14th 2015

The emerging treatment landscape for patients with high-risk multiple myeloma is burgeoning with new classes of drugs, novel agents, and fresh combination strategies that offer many promising and exciting options for future therapeutic approaches.

Monoclonal Antibody-Directed Therapies for the Management of Multiple Myeloma

May 11th 2015

Several monoclonal antibodies with multiple myeloma cell antigen or bone marrow targets have exhibited strong antimyeloma activity and may become potential therapeutic agents.

Dr. Kenneth Anderson on Combining Immunotherapies in Myeloma

May 6th 2015

Kenneth Anderson, MD, Program Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, Dana–Farber Cancer Institute discusses combining immunotherapies in myeloma.

FDA Updates Pomalidomide Multiple Myeloma Label

April 24th 2015

The FDA has updated the label for pomalidomide plus low-dose dexamethasone for multiple myeloma to include data from the phase III MM-003 study.

New Era for Monoclonal Antibodies on Horizon in Multiple Myeloma

April 12th 2015

The prospects for mAbs to change the treatment paradigm for multiple myeloma have grown considerably brighter as early-phase clinical trial results suggest that emerging agents with novel mechanisms of action are capable of delivering significant efficacy.

Dr. Vij on Tumor Bank for Multiple Myeloma at Siteman Cancer Center

April 9th 2015

Ravi Vij, MD, associate professor, medicine, Division of Oncology, Section of Bone Marrow Transplant, Siteman Cancer Center, discusses the institution's tumor banking initiative for next-generation sequencing in multiple myeloma.

Three-Drug Combos, Immunotherapy Mark Future of Myeloma Management

April 8th 2015

Sundar Jagannath, MD, discusses the latest research advances in myeloma, and how these steps will impact the future treatment paradigm for the disease.

FDA Priority Review Granted to Carfilzomib sNDA in Myeloma

March 30th 2015

An sNDA for the full approval of carfilzomib (Kyprolis) as a treatment for patients with relapsed multiple myeloma has been granted a priority review by the FDA.

FDA Accepts NDA for New Formulation of Melphalan for Myeloma

March 11th 2015

The FDA has accepted a New Drug Application (NDA) for Captisol-enabled (CE) melphalan for the treatment of patients with multiple myeloma prior to autologous hematopoietic stem cell transplantation (AHCT).

Role of Stem Cell Transplantation Evolving in Multiple Myeloma

March 11th 2015

OncLive interviewed Ravi Vij, MD, associate professor, Division of Oncology, Section of Bone Marrow Transplantation, Washington University School of Medicine and the Siteman Cancer Center, on what the future holds for stem cell transplantation in multiple myeloma.

Dr. Jagannath on Immunotherapy in Multiple Myeloma

March 10th 2015

Sundar Jagannath, MD, director of the multiple myeloma program, professor of medicine (hematology and medical oncology), Tisch Cancer Institute at Mount Sinai School of Medicine, discusses immunotherapy in multiple myeloma and how it fits into the future treatment paradigm.

2015 GU Symposium, Carfilzomib Versus Bortezomib, and More

March 6th 2015